Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Antiparkinsonian

or Psychostimulant

Use the filters below to narrow your results.

AMPA receptor antagonist (1) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Monoamine releasing agent (1) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · NMDA antagonist; GABAA potentiator (1) · Non-selective dopamine receptor agonist (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Prodrug of amphetamine + theophylline (1) · Prodrug of phenytoin; sodium channel blocker (1) · Selective M1 muscarinic antagonist (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1)

None (37) · ADHD, narcolepsy (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (39) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1)

None (39) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (39) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (37) · Oral (3) · Oral (prescribed) (1) · transdermal (1)

None (38) · 20–60 min (oral) (1) · 30–60 min (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1)

None (38) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1)

None (38) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1)

None (38) · ~22–25% (1) · ~30% (high first-pass) (1) · ~75–90% (oral) (1)

None (37) · Category C (2) · Category C (per Desoxyn label) (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

A

B

C

D

E

F

L

M

O

P

R

S

T

V

Z